摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(6,6,7,7,7-pentafluoroheptyl)-non-8-enoic acid ethyl ester | 342898-61-7

中文名称
——
中文别名
——
英文名称
2-(6,6,7,7,7-pentafluoroheptyl)-non-8-enoic acid ethyl ester
英文别名
ethyl 2-(6,6,7,7,7-pentafluoroheptyl)-8-nonenoate;ethyl 2-(6,6,7,7,7-pentafluoroheptyl)non-8-enoate
2-(6,6,7,7,7-pentafluoroheptyl)-non-8-enoic acid ethyl ester化学式
CAS
342898-61-7
化学式
C18H29F5O2
mdl
——
分子量
372.419
InChiKey
TWDRDCMBOFDGOP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.5
  • 重原子数:
    25
  • 可旋转键数:
    15
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    3-methoxy-7α-(2-propenyl)estra-1,3,5(10)-trien-17β-ol2-(6,6,7,7,7-pentafluoroheptyl)-non-8-enoic acid ethyl ester 以to give 10-[3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl]-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid的产率得到10-[3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl]-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid
    参考文献:
    名称:
    Compounds with hydroxycarbonyl-halogenoalkyl side chain
    摘要:
    本发明提供了一种化合物,包括一个基团和与该基团化学键合的基团,其中该基团包含一种在口服后具有低活性的化合物或其母体支架,并且该基团具有以下一般式(1):1其中R1代表氢原子等,R2代表C1-C7卤代烷基等,m代表2至14的整数,n代表2至7的整数,或该化合物的对映体,或其水合物或药物可接受的盐或其对映体。上述化合物在制药上具有优点,因为一般式(1)的基团使得诸如抗雌激素化合物等附加到化合物的母体支架上后,能够在口服后显示出显著增加的活性。
    公开号:
    US20030114524A1
  • 作为产物:
    描述:
    hept-6-enyl-malonic acid diethyl ester1-iodo-6,6,7,7,7-pentafluoroheptane 以to give ethyl 2-(6,6,7,7,7-pentafluoroheptyl)-8-nonenoate的产率得到2-(6,6,7,7,7-pentafluoroheptyl)-non-8-enoic acid ethyl ester
    参考文献:
    名称:
    3-ethyl-, 3-propyl- or 3-butyl-chroman and thiochroman derivatives
    摘要:
    具有以下通式(1)的化合物: 其中,R1代表乙基基团等;R2代表氢原子等;R3代表C1-C5卤代烷基团等;R4和R5各自独立地代表氢原子等;X代表氧原子或硫原子;m表示2到14的整数;n表示2到7的整数;或该化合物的对映体或水合物或药学上可接受的盐,在药物使用中具有抗雌激素活性的优点。
    公开号:
    US06552068B1
点击查看最新优质反应信息

文献信息

  • Compounds with hydroxycarbonyl-halogenoalkyl side chains
    申请人:Jo JaeChon
    公开号:US20050192449A1
    公开(公告)日:2005-09-01
    The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R 1 represents a hydrogen atom, etc., R 2 represents a C 1 -C 7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.
    本发明提供了一种化合物,该化合物由一个基团和与该基团化学键合的基团组成,其中该基团包含一种在口服后具有低活性的化合物或其母体支架,而该基团具有以下一般式(1):其中R1代表氢原子等,R2代表C1-C7卤代烷基等,m表示2到14的整数,n表示2到7的整数,或该化合物的对映体,或其合物或药学上可接受的盐。上述化合物在药学上的使用中具有优点,因为一般式(1)的基团使得诸如抗雌激素类化合物等连接到化合物的母体支架上后,在口服后能够显著增加其活性。
  • COMPOUND HAVING HYDROXYCARBONYL-HALOGENOALKYL SIDE CHAIN
    申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
    公开号:EP1241158A1
    公开(公告)日:2002-09-18
    The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1represents a hydrogen atom, etc., R2represents a C1-C7 halogenoalkyl group, etc., mrepresents an integer of 2 to 14, and nrepresents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.
    本发明提供了一种由一个分子和一个与所述分子化学键合的基团组成的化合物,其中所述分子包含口服后活性较低的化合物或其母体支架,所述基团具有以下通式(1): 其中 R1 代表氢原子等 R2 代表 C1-C7 卤代烷基等、 m 代表 2 至 14 的整数,以及 n 代表 2 至 7 的整数、 或化合物的对映体,或化合物或其对映体的合物或药学上可接受的盐。上述化合物在医药用途方面具有优势,因为通式(1)的基团可以使诸如抗雌激素类的化合物在口服后附着在化合物的母支架上,显示出显著增加的活性。
  • 3-ETHYL-, 3-PROPYL- OR 3-BUTYL-CHROMAN AND -THIOCHROMAN DERIVATIVES
    申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
    公开号:EP1241167A1
    公开(公告)日:2002-09-18
    A compound having the following general formula (1): in which R1 represents an ethyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a C1-C5 perhalogenoalkyl group, etc.; each of R4 and R5 independently represents a hydrogen atom, etc.; X represents an oxygen atom or a sulfur atom; m represents an integer of 2 to 14; and n represents an integer of 2 to 7; or an enantiomer of the compound, or a hydrate or a pharmaceutically acceptable salt of the compound or its enantiomer is advantageous in pharmaceutical use because of its anti-estrogenic activity.
    具有以下通式(1)的化合物: 其中 R1 代表乙基等 R2 代表氢原子等 R3 代表 C1-C5 全卤代烷基等; R4 和 R5 各自独立地代表氢原子等; X 代表氧原子或原子; m 代表 2 至 14 的整数;以及 n 代表 2 至 7 的整数; 或该化合物的对映体,或该化合物或其对映体的合物或药学上可接受的盐,由于其抗雌激素活性,在医药用途中具有优势。
  • Compounds with hydroxycarbonyl-halogenalkyl side chains
    申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
    公开号:EP1361205A1
    公开(公告)日:2003-11-12
    The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1represents a hydrogen atom, etc., R2represents a C1-C7 halogenoalkyl group, etc., mrepresents an integer of 2 to 14, and nrepresents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.
    本发明提供了一种由一个分子和一个与所述分子化学键合的基团组成的化合物,其中所述分子包含口服后活性较低的化合物或其母体支架,所述基团具有以下通式(1): 其中 R1 代表氢原子等 R2 代表 C1-C7 卤代烷基等、 m 代表 2 至 14 的整数,以及 n 代表 2 至 7 的整数、 或化合物的对映体,或化合物或其对映体的合物或药学上可接受的盐。上述化合物在药用方面具有优势,因为通式(1)的基团可以使诸如抗雌激素类的化合物在口服后附着在化合物的母支架上,显示出显著增加的活性。
  • Discovery of thiochroman derivatives bearing a carboxy-containing side chain as orally active pure antiestrogens
    作者:Yoshitake Kanbe、Myung-Hwa Kim、Masahiro Nishimoto、Yoshihito Ohtake、Toshiaki Tsunenari、Kenji Taniguchi、Iwao Ohizumi、Shin-ichi Kaiho、Yoshiaki Nabuchi、Setsu Kawata、Kazumi Morikawa、Jae-Chon Jo、Hee-An Kwon、Hyun-Suk Lim、Hak-Yeop Kim
    DOI:10.1016/j.bmcl.2006.04.090
    日期:2006.8
    In order to search for alternatives to the sulfoxide moiety in the long side chain of pure antiestrogens, several molecules that may interact with water in a fashion similar to ICI164,384 were designed and it was found that compounds with the carboxy, the sulfamide, or the sulfonamide instead of the sulfoxide moiety also functioned as pure antiestrogens. Interestingly, the compound possessing the carboxy moiety showed superior antiestrogen activity compared to ICI182,780 when dosed orally. Results of the pharmacokinctic evaluation indicated that the potent antiestrogen activity at oral dosing attributed to both the improved absorption from the intestinal wall and the metabolic stability of the compound in liver. (c) 2006 Elsevier Ltd. All rights reserved.
查看更多